Shares of Roche Holding AG (OTCMKTS:RHHBY – Get Free Report) have been assigned an average recommendation of “Hold” from the eleven ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $51.50.
Several brokerages have recently weighed in on RHHBY. HSBC lowered shares of Roche from a “buy” rating to a “hold” rating in a report on Monday, July 6th. Zacks Research lowered Roche from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Morgan Stanley raised Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 price target on the stock in a research note on Friday, April 24th. Finally, Argus raised Roche from a “hold” rating to a “buy” rating in a research note on Monday, April 6th.
View Our Latest Research Report on RHHBY
Institutional Trading of Roche
Roche Stock Down 2.7%
Shares of OTCMKTS RHHBY opened at $54.98 on Thursday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.38 and a quick ratio of 1.12. The company’s fifty day simple moving average is $51.70 and its 200 day simple moving average is $52.78. Roche has a 12-month low of $37.51 and a 12-month high of $60.85.
About Roche
Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).
In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.
Recommended Stories
- Five stocks we like better than Roche
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.
